ctDNA-based molecular residual disease and survival in resectable colorectal cancer
Nakamura, et al. Nature Medicine 2024
Read More
Signatera
Resources related to Signatera residual disease testing from a simple drop of blood.
-
-
SINERGY Data Summary
Read More
-
Opportunities for Signatera Testing in Head and Neck Cancer
Read More
-
Amanda Invasive Ductal Carcinoma
Hear Amanda's journey with Signatera that helped her team catch relapse earlier.
Watch Video
-
Kim Early Stage Breast Cancer Patient
How Kim's story and how Signatera served as an informative tool for post definitive treatment surveillance.
Watch Video
-
Beyond bladder cancer: A multidisciplinary approach to MRD testing in RCC
Watch Video
-
Signatera CDx Physican Brochure
Read More
-
Signatera CDx Technical Document
Read More
-
SIgnatera CDx Patient Brochure
Read More
-
Tissue Best Practices
Read More
-
Signatera Head and Neck Patient Discussion Guide
Read More
-
Signatera Lymphoma Patient Discussion Guide
Read More
-
Signatera Cancer Care Patient Discussion Guide
Read More
-
Signatera Gynecologic Patient Discussion Guide
Read More
-
Signatera Lung Patient Discussion Guide
Read More
-
Signatera CRC Patient Discussion Guide
Read More
-
Signatera Bladder Patient Discussion Guide
Read More
-
Signatera Breast Patient Discussion Guide
Read More
-
Navigating Low-Level ctDNA Positive: Interpretation, Context and Actionability
Watch Video
-
Navigating MIBC management: Integrating ctDNA into clinical practice
Watch Video
-
Loading More...
